Editorial || FREE PAPER ||
Authors Sanjay Awasthi
Published 15 August 2007 Volume 2007:1(1) Pages 1—2
Professor of Biology and Associate Vice President for Clinical Research at University of North Texas Health Sciences Center; Medical Oncologist, Texas Oncology; Partner, US Oncology
Abstract: Increasing clarity in the definition of cellular physiobiochemical mechanisms and the inter-relationships with regulatory molecules has put forth an increasingly refined framework for viewing and understanding potential therapeutic targets. The ability to synthesize and deliver as drugs, endogenous or exogenous proteins or nucleic acids in their native or altered state has also evolved along with this knowledge. Tools developed for modeling of proteins have also greatly accelerated the development of small molecule ligands developed as nominally specific drugs. Technology advancements have expanded our therapeutic armamentarium from sera to recombinant proteins, to intact cells. These novel therapeutic arts clearly did not exist in the days of old, thus deserves a name, perhaps biologics.